Actinogen Medical Limited

DB:3AC Stock Report

Market Cap: €44.2m

Actinogen Medical Management

Management criteria checks 3/4

Actinogen Medical's CEO is Steve Gourlay, appointed in Mar 2021, has a tenure of 3.75 years. total yearly compensation is A$754.11K, comprised of 54.7% salary and 45.3% bonuses, including company stock and options. directly owns 4.23% of the company’s shares, worth €1.87M. The average tenure of the management team and the board of directors is 2.3 years and 7 years respectively.

Key information

Steve Gourlay

Chief executive officer

AU$754.1k

Total compensation

CEO salary percentage54.7%
CEO tenure3.8yrs
CEO ownership4.2%
Management average tenure2.3yrs
Board average tenure7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Steve Gourlay's remuneration changed compared to Actinogen Medical's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024AU$754kAU$412k

-AU$13m

Mar 31 2024n/an/a

-AU$14m

Dec 31 2023n/an/a

-AU$15m

Sep 30 2023n/an/a

-AU$13m

Jun 30 2023AU$657kAU$396k

-AU$11m

Mar 31 2023n/an/a

-AU$11m

Dec 31 2022n/an/a

-AU$11m

Sep 30 2022n/an/a

-AU$10m

Jun 30 2022AU$955kAU$376k

-AU$9m

Mar 31 2022n/an/a

-AU$8m

Dec 31 2021n/an/a

-AU$7m

Sep 30 2021n/an/a

-AU$6m

Jun 30 2021AU$271kAU$112k

-AU$4m

Compensation vs Market: Steve's total compensation ($USD470.50K) is about average for companies of similar size in the German market ($USD468.18K).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.

CEO

Steve Gourlay (65 yo)

3.8yrs

Tenure

AU$754,111

Compensation

Dr. Steven G. Gourlay, also known as Steve, MBBS (M.D.), Ph D., FRACP, M.B.A., serves as Chief Executive Officer at Actinogen Medical Limited since March 15, 2021 and as its Managing Director and Director...

Leadership Team

NamePositionTenureCompensationOwnership
Steven Gourlay
MD, CEO & Director3.8yrsAU$754.11k4.23%
€ 1.9m
William Souter
Chief Financial Officerless than a yearAU$476.62k0.013%
€ 5.8k
Dana Hilt
Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board1.8yrsAU$913.27kno data
Michael Roberts
Head of Investor Relations & Corporate Communications3.6yrsno datano data
Paul Rolan
Head of Clinical Pharmacology & Lead Physician and Depression2.8yrsAU$191.66kno data
Fujun Li
Head of Manufacturing1.3yrsno datano data
Andrew Udell
Chief Commercial Officerless than a yearno datano data
Peter Webse
Company Secretary11.2yrsno datano data

2.3yrs

Average Tenure

63yo

Average Age

Experienced Management: 3AC's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Steven Gourlay
MD, CEO & Director3.8yrsAU$754.11k4.23%
€ 1.9m
Dana Hilt
Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board2.9yrsAU$913.27kno data
George Morstyn
Independent Non-Executive Director7yrsAU$114.27k0.44%
€ 196.3k
Geoffrey Edward Brooke
Independent Non-Executive Chairman7.8yrsAU$234.39k0.67%
€ 295.2k
Colin Masters
Member of Xanamem Clinical Advisory Board9.8yrsno datano data
Jeffrey Cummings
Member of Xanamem Clinical Advisory Board9.8yrsno datano data
Malcolm McComas
Independent Non-Executive Director5.7yrsAU$114.27k0.27%
€ 117.6k
John Harrison
Member of Depression & Cognition Clinical Advisory Board2.9yrsno datano data
Craig Ritchie
Chairman of Xanamem Clinical Advisory Board9.8yrsno datano data
Jonathan Seckl
Member of Scientific Advisory Boardno datano datano data
Brian Walker
Member of Scientific Advisory Boardno datano datano data
Scott Webster
Member of Scientific Advisory Boardno datano datano data

7.0yrs

Average Tenure

71yo

Average Age

Experienced Board: 3AC's board of directors are considered experienced (7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 02:50
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Actinogen Medical Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tara SperanzaBell Potter
Pooya HemamiEdison Investment Research